https://biostrateon.com/insights Life sciences M&A, fundraising and strategy from Biostrateon. en-gb Mon, 19 Oct 2026 10:51:34 GMT https://biostrateon.com/insights/frontier-ai-is-coming-for-bio-which-moats-survive https://biostrateon.com/insights/frontier-ai-is-coming-for-bio-which-moats-survive Tue, 06 Oct 2026 00:00:00 GMT Part 2 of our frontier AI x bio series: the five ways AI x bio moats fail as frontier labs absorb the stack, and the four positions that survive. The BioStrat Brief https://biostrateon.com/insights/life-sciences-at-anthropic-openai-google-nvidia-and-others-ai-labs https://biostrateon.com/insights/life-sciences-at-anthropic-openai-google-nvidia-and-others-ai-labs Tue, 08 Sep 2026 00:00:00 GMT Part 1 of our frontier AI x bio series: what the labs actually shipped in biology, what has been validated, and why the moat has moved from the model to the loop. The BioStrat Brief https://biostrateon.com/insights/the-changing-wave-of-ai-adoption-in-pharma-from-molecules-to-models https://biostrateon.com/insights/the-changing-wave-of-ai-adoption-in-pharma-from-molecules-to-models Tue, 25 Aug 2026 00:00:00 GMT Pharma has moved from partnering for AI-made molecules to licensing models and owning the capability. Rent, build or buy: how to choose, and what it means for techbio. The BioStrat Brief https://biostrateon.com/insights/what-founders-get-wrong-about-the-fundraise https://biostrateon.com/insights/what-founders-get-wrong-about-the-fundraise Tue, 04 Aug 2026 00:00:00 GMT Practical lessons from life sciences fundraises: lead with your strongest card, size the round to the milestone, build a capital stack and read past the headline valuation. The BioStrat Brief https://biostrateon.com/insights/the-discipline-of-engineering-a-lucrative-exit https://biostrateon.com/insights/the-discipline-of-engineering-a-lucrative-exit Sun, 26 Jul 2026 00:00:00 GMT Exits are engineered years before the data room opens. Seven self-inflicted mistakes that quietly kill life sciences deals, and the timeline that avoids them. The BioStrat Brief https://biostrateon.com/insights/the-pharma-commercial-services-model-that-worked-for-decades-is-rewiring https://biostrateon.com/insights/the-pharma-commercial-services-model-that-worked-for-decades-is-rewiring Mon, 06 Jul 2026 00:00:00 GMT Agentic AI is repricing the seat between pharma's commercial intent and customer behaviour. Which layers of commercial services melt, which survive, and what the deal tape says. The BioStrat Brief https://biostrateon.com/insights/how-platform-biotechs-can-win-in-an-asset-obsessed-market-a-fundraising-playbook https://biostrateon.com/insights/how-platform-biotechs-can-win-in-an-asset-obsessed-market-a-fundraising-playbook Tue, 30 Jun 2026 00:00:00 GMT Investors now ask platform founders for an asset first. How to engineer a venture-ready platform proof of concept and pitch it with the 60/40 framework. The BioStrat Brief https://biostrateon.com/insights/accelerating-inorganic-growth-through-m-and-a-life-sciences-informatics https://biostrateon.com/insights/accelerating-inorganic-growth-through-m-and-a-life-sciences-informatics Thu, 11 Dec 2025 03:33:10 GMT Defined M&A strategy and built a prioritized acquisition funnel of 25 companies from 750, enabling a PE-backed platform to accelerate inorganic growth. Case Studies https://biostrateon.com/insights/rwd-market-assessment-for-market-entry-data-curation-platform https://biostrateon.com/insights/rwd-market-assessment-for-market-entry-data-curation-platform Tue, 22 Jul 2025 00:00:00 GMT Evaluated the real-world data (RWD) market to assess pricing, key use cases, and unmet needs for a data harmonization AI start-up exploring market entry. Case Studies https://biostrateon.com/insights/digital-twins-in-healthcare-and-drug-discovery-from-idea-to-success-stories https://biostrateon.com/insights/digital-twins-in-healthcare-and-drug-discovery-from-idea-to-success-stories Sun, 20 Apr 2025 00:00:00 GMT Exploring the transformative potential of digital twins in healthcare and pharmaceutical research. Articles https://biostrateon.com/insights/5-pitfalls-ai-healthcare-start-ups-need-to-avoid-early-in-their-journey https://biostrateon.com/insights/5-pitfalls-ai-healthcare-start-ups-need-to-avoid-early-in-their-journey Tue, 15 Apr 2025 00:00:00 GMT Essential guidance for AI healthcare startups on navigating common challenges and ensuring sustainable growth. Articles https://biostrateon.com/insights/start-up-strategy-support-nash-diagnostics-ai-platform https://biostrateon.com/insights/start-up-strategy-support-nash-diagnostics-ai-platform Tue, 11 Mar 2025 00:00:00 GMT Helped a newly formed company shape their product development and go-to-market strategy, secured a key partnership with a top Australian university KOL, and provided fundraising strategy and pitching coaching. Case Studies https://biostrateon.com/insights/from-lab-coats-to-logins-cloud-labs-and-their-role-in-reinventing-the-future-of https://biostrateon.com/insights/from-lab-coats-to-logins-cloud-labs-and-their-role-in-reinventing-the-future-of Sun, 28 Apr 2024 00:00:00 GMT All scientists have at one point wished to have work from home and or the capability just to design new experiments and analyze data while letting a technical staff experiment in the lab on their behalf. Articles https://biostrateon.com/insights/adopting-ai-platforms-a-structured-framework-for-thoughtful-platform-evaluation https://biostrateon.com/insights/adopting-ai-platforms-a-structured-framework-for-thoughtful-platform-evaluation Mon, 15 Jan 2024 00:00:00 GMT A comprehensive guide to evaluating and implementing AI platforms in pharmaceutical research and development. Articles https://biostrateon.com/insights/biogpt-a-game-changer-for-pharma-and-healthcare https://biostrateon.com/insights/biogpt-a-game-changer-for-pharma-and-healthcare Sat, 05 Aug 2023 00:00:00 GMT An analysis of BioGPT's potential impact on pharmaceutical research and healthcare delivery. Articles https://biostrateon.com/insights/artificial-intelligence-for-better-antibody-drugs-ready-for-prime-time https://biostrateon.com/insights/artificial-intelligence-for-better-antibody-drugs-ready-for-prime-time Wed, 12 Jul 2023 00:00:00 GMT Examining the current state and future potential of AI in antibody drug development. Articles https://biostrateon.com/insights/the-ai-productivity-game-in-pharma https://biostrateon.com/insights/the-ai-productivity-game-in-pharma Wed, 28 Jun 2023 00:00:00 GMT Analyzing how pharmaceutical companies can leverage AI to enhance productivity and innovation. Articles https://biostrateon.com/insights/buyers-market-in-pharma https://biostrateon.com/insights/buyers-market-in-pharma Mon, 24 Apr 2023 00:00:00 GMT **2023 will likely stay a Buyer’s market in the biopharma and life sciences M&A** Articles https://biostrateon.com/insights/tech-providers-or-biotechs-the-quest-for-an-optimal-business-model-in-ai-drug https://biostrateon.com/insights/tech-providers-or-biotechs-the-quest-for-an-optimal-business-model-in-ai-drug Fri, 19 Mar 2021 00:00:00 GMT An analysis of evolving business models in the AI-driven drug discovery landscape. Articles